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ORTHOUNION is a multicentre, open, comparative, three-arm, randomized clinical trial (EudraCT number 2015-000431-32) to
compare the eﬃcacy, at one and two years, of autologous human bone marrow-derived expanded mesenchymal stromal cell
(hBM-MSC) treatments versus iliac crest autograft (ICA) to enhance bone healing in patients with diaphyseal and/or
metaphysodiaphyseal fracture (femur, tibia, and humerus) status of atrophic or oligotrophic nonunion (more than 9 months
after the acute fracture, including recalcitrant cases after failed treatments). The primary objective is to determine if the
treatment with hBM-MSCs combined with biomaterial is superior to ICA in obtaining bone healing. If conﬁrmed, a secondary
objective is set to determine if the dose of 100× 106 hBM-MSCs is noninferior to that of 200× 106 hBM-MSCs. The participants
(n = 108) will be randomly assigned to either the experimental low dose (n = 36), the experimental high dose (n = 36), or the
comparator arm (n = 36) using a central randomization service. The trial will be conducted in 20 clinical centres in Spain,
France, Germany, and Italy under the same clinical protocol. The conﬁrmation of superiority for the proposed ATMP in
nonunions may foster the future of bone regenerative medicine in this indication. On the contrary, absence of superiority may
underline its limitations in clinical use.
1. Introduction
Bone injuries represent an important medical problem
worldwide, producing signiﬁcant healthcare and societal
expenditure. In Europe, complex fractures are increasing in
frequency due to severe traumatic injuries, such as traﬃc
accidents, presently with higher survivorship of polytrauma
patients. While most bone injuries are capable of healing
through bone regeneration by natural callus formation with
standard treatments, long bone injuries may not heal,
impairing the patient’s life and becoming an important
unmet clinical need.
Nonunions, also known as pseudarthrosis, may occur in
5% to 20% of long bone fractures that fail to heal properly,
with morbidity, prolonged hospitalization, and increased
expenses [1, 2]. Clinical consensus is lacking regarding the
deﬁnition of nonunions [3]. Nonunions are frequently
deﬁned under the FDA guidance [4], and the absence of
consolidation more than 9 months after the index fracture
without evidence of progressive signs of bone healing are
widely used criteria. Furthermore, nonunions are classiﬁed
based on the biologic potential of bone healing [5]. Since
Weber and Cech (1976), quoted by Müller et al. [6], atrophic
nonunion is associated with poor vascularity and shows
insuﬃcient bone bridging to stabilize the fracture, insuﬃ-
cient bone biological activity in the fracture, and failure of
previous treatments. These require augmentation to procure
bone healing, and the current standard treatment considered
as the benchmark is autologous bone grafting, obtained from
the same patient at a diﬀerent surgical site and transplanted
to the reconstruction site.
The iliac crest holds a reservoir of spongious bone that is
frequently used as a source of bone autograft, providing
extracellular matrix (for osteoconduction), growth factors
(modulating bone healing as per osteoinduction), and
patient’s cells (leading to local osteogenesis). However, major
complications in 5% of the cases have been reported, includ-
ing donor defect hernias, vascular injuries, sciatic nerve
injury, deep infection, deep haematoma requiring transfu-
sion, and iliac wing fracture. Minor related complications
include pain at the extraction site in 5% cases, superﬁcial hae-
matoma or seroma or superﬁcial infection at the extraction
site in 13% cases, and ilioinguinal neuralgia in 2% cases [7].
Other limitations of iliac crest autograft (ICA) fostering
research for alternatives include limited amount of available
bone (particularly if previous harvesting and replacement
by ﬁbrous tissue) and limited eﬃcacy. Although a bench-
mark, insuﬃcient information about iliac crest autograft
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eﬃcacy is available from the literature. When used as a con-
trol, a recent multicentric trial with 61 patients treated with
autograft observed 74% radiological consolidation (45/61)
by rigorous criteria (bridging in at least three of four views)
at 9 months, even if only 25% of these cases were atrophic
nonunions [8].
Culture-expanded autologous MSCs combined with
biomaterial granules as carrier agents have been proposed
as a promising technology to substitute bone autograft to
augment nonunions in early feasibility studies [9, 10]. How-
ever, studies and publications vary regarding the origin of
MSCs, the expansion protocol, the reproducibility and vari-
ability of the cell product, the quality of this cell product at
delivery, the demographics of the treated patients, the diag-
nostic criteria of nonunion in the inclusion criteria, the bone
healing criteria, the safety reporting, and the follow-up. Most
importantly, the conﬁrmed dose in the implanted cell prod-
uct is unclear, and previous trials just declare to implant the
maximum cell dose that can be generated by the available
technology at the facility producing the cell expansion.
Signiﬁcant preclinical work including quality assessment
and standardisation of the cell product to be implanted is
required before a cell product can obtain the approval for a
certain trial as an investigational medicinal product (IMP)
on an advanced therapy medicinal product (ATMP) under
good manufacturing practices (GMP), in compliance with
European regulation [11]. Besides, signiﬁcant eﬀorts in the
design of a wide multicentric trial are required to conﬁrm
safety and prove eﬃcacy, with adequate randomization
against a widely accepted control, in a patient population
precisely deﬁned by speciﬁc inclusion and exclusion criteria.
As part of the EU-FP7-REBORNE project (GA 241879),
the procedures of isolation, culture, and characterization of
expanded human bone marrow-derived mesenchymal stro-
mal cells (hBM-MSCs) cultured in platelet lysate (PL) were
fully standardized and validated by multiple GMP produc-
tion facilities in France, Italy, Germany, and Spain. The ther-
apeutic doses obtained at release and used in the early clinical
trial within the REBORNE project were 100× 106 and
200× 106 hBM-MSC cells. Cells adhered to a CE-marked
granulated biphasic bioceramic and were delivered to the
bone injury by open surgery after nonunion site surgical
preparation. The osteogenic potential was preclinically stud-
ied both in vitro and in vivo [12, 13]. The tumorigenicity and
migration of human MSCs derived from BM (tumorigenicity
and biodistribution) were also preclinically studied in
NOD SCID mice [14]. After validation among the GMP
manufacturing centres from the four participating countries,
the IMP was approved for safety and feasibility clinical trials
for nonunion fractures (EudraCT number 2011-005441-13)
and for avascular necrosis of femoral head (EudraCT number
2012-002010-39). No safety events related to the IMP were
detected for any of these early trials. At this point, the evalu-
ation of eﬃcacy against the standard is still required to sup-
port the future clinical application of this technique.
MBCP+™ (Biomatlante, France) is a class III implant of
wide use, CE marked (CE0123) and FDA 510(k) approved.
It is a biphasic material composed of HA/β-TCP in a ratio
of 20/80 in weight, resorbable and able to be rapidly replaced
by newly formed bone [15]. The biomaterial was selected due
to preclinical studies that conﬁrmed high colonization of the
biomaterial by osteogenic cells [16] and due to proven safety
and eﬃcacy of the MBCP+ alone or combined with expanded
MSCs [14–16] at the selected dose [17, 18].
As a part of the EU-H2020-ORTHOUNION project
(GA 733288), the global aim of this ORTHOUNION clinical
trial is to overcome the major hurdle to complete the trans-
lation to clinical application. Therefore, the ORTHOU-
NION proposal focuses on testing the eﬃcacy of expanded
BM-hMSC in two diﬀerent doses (100 and 200× 106 cells),
versus iliac crest bone autograft, the currently accepted stan-
dard therapy, to biologically augment surgical treatment of
long bone nonunions.
2. Material and Methods
2.1. Trial Characteristics and Design. ORTHOUNION is a
multicentre, open, comparative, randomized, clinical trial
with three parallel arms to evaluate the eﬃcacy at one and
two years of two doses of an ATMP against iliac bone auto-
graft to enhance bone healing in patients with long bone non-
union (EudraCT number 2015-000431-32). A total of 108
patients will be randomly assigned to either the experimental
low-dose arm, experimental high-dose arm, or the active
comparator arm (ICA) with a 1 : 1 : 1 allocation using a cen-
tral randomization service. The experimental low dose con-
tains a total number of 100× 106 hBM-MSCs suspended in
5% human albumin up to a total volume of 10mL (cell con-
centration of 10× 106). The experimental high dose contains
a total number of 200× 106 hBM-MSCs suspended in 5%
human albumin up to a total volume of 10mL (cell concen-
tration of 20× 106). Each experimental dose will be combined
with 10 cc of the granulated biomaterial MBCP+ (Bioma-
tlante, Nantes, France). The trial will be conducted in 20 clin-
ical investigational sites in four European countries (France,
Germany, Italy, and Spain) under the same clinical protocol
and standardized surgical techniques. The cell product
derived from autologous hBM-MSCs will be expanded in
4 diﬀerent GMP manufacturing facilities in France (EFS
Ile de France, Centre de Thérapie Cellulaire de Créteil),
Germany (Institut für Klinische Transfusionsmedizin und
Immungenetik Ulm Gemeinnützige GmbH (IKT Ulm),
DRK-Blutspendedienst Baden-Würrtemberg–Hessen und
Universitätsklinikum Ulm, Ulm), Italy (Fondazione IRCCS
Ca’ Granda Ospedale Maggiore Policlinico, Cell Factory
“F. Calori”, Milano), and Spain (Unidad de Producción
Celular UPC, Hospital Puerta de Hierro-Majadahonda,
Universidad Autónoma de Madrid, Servicio de Hematología
y Hemoterapia, Madrid).
2.2. Study Objectives. The primary objective is to determine if
the combined treatment of the ATMP, hBM-MSC+biomate-
rial (G2), is superior to the control, iliac crest autologous graft
(G1), to obtain radiological and clinical bone consolidation at
12 months after surgery of diaphyseal and/or metaphysodia-
physeal (femur, tibia, and humerus) atrophic or oligotrophic
nonunions after a fracture (more than 9 months after the
acute fracture and insuﬃcient bone bridging to stabilize the
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fracture, insuﬃcient bone biological activity in the fracture,
and failure of previous treatments). The secondary objectives
(SO) are the following: (SO1) to determine if the low dose of
hBM-MSC+biomaterial (G2b) is noninferior to the high dose
of hBM-MSC+biomaterial (G2a) to obtain radiological
consolidation at 12 months after surgery of diaphyseal and/
or metaphysodiaphyseal (femur, tibia, and humerus) non-
unions after an unhealed fracture; (SO2) to compare the per-
centage of bone consolidation between the G1 and G2
treatment arms at 6 and 24months after surgery and between
the G2a and G2b treatment arms at 6, 12, and 24 months
after surgery; (SO3) to compare the radiological consolida-
tion between the G1 and G2 treatment arms and between
G2a and G2b treatment arms, at baseline and 6, 12, and 24
months after surgery; (SO4) to compare pain with and with-
out weight bearing using the Numeric Rating Scale (from 0 to
10) between the G1 and G2 treatment arms and between G2a
and G2b treatment arms, at baseline and 6, 12, and 24
months after surgery; (SO5) to compare the rate of further
surgical intervention at the callus site between the G1 and
G2 treatment arms and between G2a and G2b treatment
arms at 6, 12, and 24 months after surgery; (SO6) to compare
the early and global complication rate between the G1 and
G2 treatment arms and between G2a and G2b treatment
arms at 6, 12, and 24 months after surgery; (SO7) to assess
the safety of autologous hBM-MSCs between the G1 and
G2 treatment arms at 6, 12, and 24 months after surgery;
(SO8) to identify the factors associated with bone consolida-
tion between the G1 and G2 treatment arms and between
G2a and G2b treatment arms at 6, 12, and 24 months after
surgery; and (SO9) to compare the physical and mental
health status using the SF-36 Health Survey at baseline and
6, 12, and 24 months after surgery. Outcome measures are
described in Table 1.
2.3. Patient Population and Evaluation. Each investigator
will enroll eligible patients into the trial (after obtaining
the signature of the due informed consent adapted to each
national regulation) and will enter patient data into the
eCRF timely throughout the study. Inclusion and exclusion
criteria are shown in Table 2. During the inpatient stay,
recovery, and follow-up, all participants will receive conven-
tional treatment.
A clinical trial committee, composed by three indepen-
dent expert clinicians, will review and adjudicate the primary
eﬃcacy outcomes (bone consolidation) and other collected
clinical outcomes, using prespeciﬁed deﬁnitions and
methods described in the Clinical Event Committee Charter.
Files for adjudication will be prepared and accordingly
blinded prior to adjudication.
Blood samples will be obtained for routine blood tests,
serology tests (HIV-, syphilis, HBV, and HCV), and bone
turnover marker tests (bone-speciﬁc alkaline phosphatase
(BAP), C-terminal propeptide of type I procollagen (PICP),
osteocalcin N-terminal fragment (Midtact-OC), carboxy-
terminal cross-linked telopeptide of type I collagen (beta-
CTX), osteoprotegerin (OPG), receptor activator of nuclear
factor NF-kappa B ligand (RANKL)). Flow diagrams of the
trial are shown in Figures 1 and 2.
2.4. Treatments. The active comparator treatment (augmen-
tation with spongious ICA) is a surgical procedure consid-
ered the standard of care, which requires the extraction of
the needed spongious bone graft from the iliac crest at non-
union surgery. The experimental treatment (augmentation
with autologous hBM-MSCs combined with the previously
described CE-marked biphasic bioceramic) includes expan-
sion of MSCs under GMP conditions in associated facilities.
For both experimental arms (G2a and G2b), expanded autol-
ogous hBM-MSCs will be mixed in the surgical setting,
immediately before implantation, with the previously
described biomaterial called MBCP+, a class III, CE-marked,
and FDA-approved biomaterial, provided by Biomatlante
(Nantes, France) in a syringe ready to use. Table 3 summa-
rizes the study arms.
2.5. Surgical Interventions. The preparation of the nonunion
site will be the same for both interventions. It will consist in
the ablation of the necrotic bone fragments and intercalated
ﬁbrous tissue within the nonunion, followed by bone decor-
tication to create a vascularized bed in which the cell com-
posite or the autograft will be placed.
2.5.1. Iliac Crest Grafting. The ICA will be obtained as per
standard surgical technique. The appropriate incision after
skin preparation will expose the anterior iliac crest, followed
by blunt dissection. Once exposed, the surgeon will decide on
the most appropriate trephines and dowels to be used to con-
servatively obtain the required spongious graft that will be
preserved through the case in a separate container, as per
standard of care. If insuﬃcient autograft to ﬁll and cover
the nonunion is harvested, the incision and crest approach
may be extended so the harvesting fulﬁls the bone graft
needs. Usually, one single anterior iliac crest suﬃces to cover
the autograft needs of about 10 cc for each case (similar vol-
ume to the implanted biomaterial in the experimental arm).
In case of insuﬃcient bone in the exposed iliac crest (due to
previous harvesting or other surgical issues), the contralateral
crest may be exceptionally required. By no means will the
surgeon obtain insuﬃcient bone autograft to complete the
surgical requirements. The wound will be closed following
muscle, fascia, and subcutaneous layer closure. A drain
may be used if found necessary by the surgeon in charge
of the case.
2.5.2. Bone Marrow Mesenchymal Stem Cells +Biomaterial
Implantation. First, the bone marrow will be harvested under
loco-regional (epidural, spinal) or general anaesthesia. Bone
marrow will be aspirated from the anterior or posterior iliac
crests, after insertion of a bevelled needle (6 to 8 cm in length
and 1.5mm in internal diameter) into the spongy bone, and
transferred into a 20mL plastic syringe with 1mL of heparin.
At a given depth, the needle will be turned 45° to reorient the
bevel during successive aspirations, so that the largest possi-
ble space is aspirated. After one full turn, the needle will be
moved 1 cm toward the surface through the same insertion
site, and aspirations will again be performed, with the needle
always turned 45° after each aspiration. The marrow will be
aspirated in small fractions (3–4mL) to reduce the degree
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of dilution by peripheral blood. A total of 30–35mL of
bone marrow will be aspirated. If necessary, two or three
perforations will be performed, through the same skin
opening, into the iliac crest, with the perforations spaced
approximately 2 cm from each other to avoid dilution by
aspiration in the previous hole. All aspirates will be pooled
in plastic bags containing an anticoagulant solution. The
bone marrow will be then forwarded to the associated
GMP facilities. The ﬁnal product of expanded MSCs will
be manufactured according to GMP rules using aseptic pro-
cedures and disposable sterile single-use supplies for all
product contact steps. The whole process will be conducted
in accordance with written procedures and each step will be
recorded on batch. All manipulations involving the initial
preparation of cells, cell culture, and cell packaging will be
performed in clean rooms of appropriate class of air clean-
liness. The batch production records for each lot require
documentation and conﬁrmation signatures that the proce-
dures have been followed. Brieﬂy, MSCs will be cultured
and expanded using alpha MEM medium supplemented
with PL [19]. Cells will be conditioned in a syringe for
injection. The ﬁnal product will consist of fresh, autologous
bone marrow MSCs, expressing the markers CD90, CD73,
CD105 and negative for CD14 and CD45 and HLA class
II, with a 90% viability rate, at a dose of 100× 106 or
200× 106 cells (G2a and G2b) suspended in 5% human
albumin up to 10mL (the delivery contains two syringes
of 5mL each).
Secondly, the conduction of the surgery will be the same
as for bone autograft, except for the implantation of the com-
posite (hBM-MSCs+biomaterial). The mixture will be pre-
pared in the operating room as per protocol [20] and
placed in the previously prepared area to be grafted. Each
5mL cell product syringe is mixed with 5 cc of biomaterial
(1-2mm MBCP+ granules) ﬁlling the intergranular pores.
The ﬁnal mixture of the biomaterial and cells has a pasty con-
sistency and it will be preferably introduced within the gap of
the nonunion. Circumferential use of the material will only
be performed when the bone gap is ﬁlled.
In both cases, a stable ﬁxation of the fracture will be
required. The use of an osteosynthesis system may include
static or locked nail, locked or unlocked bone plate with
screws, and/or external ﬁxator (including the Ilizarov sys-
tem) when other means are not adequate. Furthermore, the
surgical technique will be reevaluated postoperatively by
the clinical trial committee, to conﬁrm the predeﬁned cri-
teria of a satisfactory surgical procedure (stable ﬁxation
and adequate augmentation) to validate the analysis of the
case as per protocol. These criteria include absence of major
complications after the procedure (intraoperative fracture,
deviation, inadequate reduction, or other surgical gestures
or interventions, except ﬁbular osteotomy if required for
compression or reduction of a tibial nonunion), presence
of suﬃcient biomaterial or graft (ﬁlled nonunion gap, pres-
ence of suﬃcient graft/material in the fracture compression
side and not in the tension side), and suﬃcient ﬁxation
(detecting immediately after surgery what could be consid-
ered an unstable ﬁxation or unstable nail or other subopti-
mal techniques).
Table 2: ORTHOUNION clinical trial inclusion/exclusion criteria.
Inclusion criteria
(1) Age 18 to 65, both sexes
(2) Traumatic isolated closed or open Gustilo I and II, IIIA and
IIIB humerus, tibial or femur diaphyseal, or
metaphysodiaphyseal fracture with a status of atrophic,
oligotrophic, or normotrophic nonunion. A nonunion is
deﬁned as a fracture not healed at least 9 months after the
originating trauma that meets the following criteria:
(i) Insuﬃcient bone bridging to stabilize the fracture
(ii) Insuﬃcient bone biological activity in the fracture
(iii) Failure of previous treatment (including bone grafting)
(3) At least 9 months from acute fracture
(4) Able to understand, accept, and sign informed consent
(5) Medical health coverage
(6) Able to understand and accept the study constraints
Exclusion criteria
(1) Hypertrophic nonunions
(2) Segmental bone loss requiring speciﬁc therapy
(bone transport, vascularized graft, large structural allograft,
megaprosthesis, etc.)
(3) Unrecovered vascular or neural injury
(4) Other fractures causing interference with weight bearing
(5) Visceral injuries or diseases interfering with callus formation
(severe cranioencephalic trauma, etc.)
(6) Active infection of any location and aetiology
(7) Surgical contraindication of any cause
(8) Pregnancy, breast-feeding women, and women who are of
childbearing age and not practicing adequate birth control. The
following methods are considered adequate:
(i) Combined hormonal contraception
(ii) Injected hormonal contraception
(iii) Implanted hormonal contraception
(iv) Progesterone-only hormonal contraception associated
with inhibition of ovulation
(v) Placement of an intrauterine device (IUD)
(vi) Placement of intrauterine hormone-releasing system
(IUS)
(9) Malignant tumour (past history or concurrent disease) (except
carcinoma in situ or basalioma in remission)
(10) History of bone harvesting on iliac crest contraindicating
new iliac crest bone graft harvesting or bone marrow
collection
(11) Insulin-dependent diabetes
(12) Any evidence (conﬁrmed by PCR) of active infection with
HIV, hepatitis B, or hepatitis C
(13) Any evidence of syphilis
(14) Known allergies to products involved in the production
process of MSC
(15) Corticoid or immunosuppressive therapy more than one week
in three months prior to study inclusion
(16) Autoimmune inﬂammatory disease
(17) Current treatment by bisphosphonates not stopped three
months prior to study inclusion
(18) Impossibility to meet at the appointments for the
follow-up
(19) Participation in another therapeutic trial in the previous
3 months
(20) Second nonunion in case of bilateral or multiple
nonunions (only one nonunion per patient will be included
in the trial)
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3. Statistical Analysis
3.1. Sample Size
3.1.1. Test of Superiority (Primary Endpoint) for G1 versus G2
Comparison. For an allocation 1 : 2 to test the percentage of
bone consolidation between G1 and G2, the sample size of
36 in comparator arm (ICA) and 72 in experimental arm
(hBM-MSC) achieve more than 80% power to detect superi-
ority with a clinically meaningful margin of superiority of
20%, considering a 5% loss. Despite the uncertainties derived
from the fact that no head-to-head comparisons have been
tested in well-designed randomized clinical trials, literature
data suggest that the control arm (G1) may have a rate of
74% in eﬃcacy [8] and that it is reasonable to expect 20%
superiority for the rate of responders in the experimental
arm (G2a+G2b) [21, 22]. The signiﬁcance level of the test
will be established at the 2.5% one-sided alpha level (equiva-
lent to 5% two-sided alpha level).
3.1.2. Test of Noninferiority (Secondary Endpoint) for G2a
and G2b Comparison. The sample size for the assessment of
the noninferiority of G2b in front of the G2a arms will be
based on the REBORNE scale. A total sample size of 72 par-
ticipants with 36 in group G2a and 36 in group G2b will
Randomization (allocation 1 : 1 : 1)
Eligibility population
Screening authorization
Completed baseline
assessment
Not randomized due to
(i) inclusion criteria,
(ii) exclusion criteria,
(iii) other.
SpainFrance Germany Italy
G1:
Comparator arm
(Iliac crest autologous
graft) n = 36
Efficacy and safety FU
(24 months postop)
End of study
Primary efficacy evaluation
(12 months postop)
G2:
experimental arm
(hMSC + biomaterial)
n = 72
Main
analysis:
superiority
comparison
Secondary analysis:
noninferiority comparison
Loss in FU
Loss in FU
Loss in FU
Loss in FU
Loss in FU
Loss in FU
G2b:
Experimental arm
(hBM-MSC + biomaterial)
Low dose
n = 36
G2a:
Experimental arm
(hBM-MSC + biomaterial)
High dose
n = 36
Primary efficacy evaluation
(12 months postop)
Primary efficacy evaluation
(12 months postop)
Efficacy and safety FU
(24 months postop)
End of study
Efficacy and safety FU
(24 months postop)
End of study
Figure 1: CONSORT diagram of the ORTHOUNION clinical trial.
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achieve more than 90% power to establish the noninferiority
using a one-sided 2.5% alpha level. The margin of noninferi-
ority is 10% on the ratio of means, assuming that the true
ratio is 1.0 (i.e., G2a and G2b have the same eﬀect). The coef-
ﬁcients of variation of both groups are assumed to be around
0.1349 based on internal data, with a mean of 0.113 and a SD
of 0.815 [23].
All sample size calculations have been performed using
the nQuery v7.0 validated software [24].
3.2. Plan of Analysis. Primary and secondary endpoints and
the statistical plan of analysis are described in Table 1. Five
subgroups for analysis are declared: manufacturing site
(Spain, France S1, France S2, Germany, and Italy); anatomical
START: screening (day 30)
Informed consent signature
Inc/exc criteria
CE, NRS, LT, ST, BS, PT ⁎, xR⁎, CT⁎
Surgery
(Day 15 or 21)
CE, NRS, AE
End: Month 24
CE, NRS, xR, RS, SF-36, EQ, AE
Visit 9
Left, only for
iliac crest
autograft arm
(ICA arm)
Right, only for
bone marrow-
mesenchymal stem cells
+ biomaterial arms
(BM-MSC + B arm)
Both doses
Visit 0
AE: verification of adverse event
An: anaesthesiology consults
BS: blood sample for bone turnover markers
CE: clinical examination
CT: computerized tomography
CTEB: clinical trial executive board
EQ: EuroQoL survey
LT: routine laboratory test
NRS: Numeric Rating Scale for pain
PC&PD: patient card and patient diary
postop: postoperation
PT: pregnancy test
RS: radiological score (REBORNE scale)
SF-36: short form-36 health survey
ST: serology test
xR: X-ray
⁎ If needed
CTBE evaluation
Inc/exc criteria verification
Randomization
Presurgical visit
Assignment communication
Citation for intervention
CE, SF-36, EQ, NRS, RS, An, PC&PD
Visit 1
(Day 1)
Bone marrow harvesting
CE, AE, ST⁎
Not
applicable
Day before surgery
LT, PT ⁎, AE
Visit 3
Surgery
Iliac crest grafting
CE, NRS, xR, AE
Visit 4
Month 1.5 postop
CE, NRS, xR, EQ, AE, BS
Visit 5
Month 3 postop
CE, NRS, xR, EQ, AE, BS
Visit 6
Month 6 postop
CE, NRS, xR, CT, RS, SF-36, EQ, AE, BS
Visit 7
Month 12 postop
CE, NRS, xR, RS, CT, SF-36, EQ, AE
Visit 8
Visit 2
Figure 2: Flow diagram of the ORTHOUNION clinical trial.
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site: femur, humerus, and tibia; time (months) since acute
fracture; smoking habits (yes/no); and sex (female/male).
For these, Fisher’s exact test for categorical variables, t-test
or one-way ANOVA for Gaussian distributed variables,
Mann–Whitney test and Kruskal-Wallis for non-Gaussian
continuous variables will be used.
The plan of analysis will be tested in the following two
populations of analysis: (a) modiﬁed full analysis set (mFAS)
that will include all patients who have received treatment;
(b) per protocol population (PP) that will include those
patients in the mFAS set without major protocol deviations.
Procedures to account for missing or spurious data will
include patients whose information on consolidation is
unknown at the end of the trial and will be considered fail-
ures, irrespectively, to the drop-out reason. With regard to
the radiological consolidation, the baseline value will be used
to impute the missing case; in case of treatment-related
missing data, the missing case is not imputed otherwise.
No formal imputations will be performed for the rest of var-
iables, and the analyses will be based on the Available Data
Only (ADO) approach.
4. Discussion
There is a lack of multicentric, randomized clinical trials in
the literature, capable of deﬁning the value of current regen-
erative medicine strategies based on MSCs. Bone healing in
diﬃcult clinical settings has gathered multiple early trials
with cell therapy, but the available evidence is limited.
Nonunions after long bone fractures are a challenging
scenario to evaluate the eﬃcacy of cell therapy or other com-
peting technologies. Furthermore, the severity of the included
cases may impact the results. Delayed unions of the tibia were
healed by bone marrow MSCs and platelet-rich plasma [25],
but obviously the severity of the cases was limited. Clinical
trials on the treatment of long nonunions frequently include
any type of nonunion, from hypertrophic to oligotrophic or
atrophic, and the results may be impacted by the case mix.
A reference multicentric trial [8] included 25% atrophic
nonunions in the control arm versus 42% in the experimen-
tal arm. To solve this issue, our trial will exclude hypertro-
phic nonunions.
The control arm in comparative trials about bone healing
is a diﬃcult choice. Although iliac crest autograft has long
been considered the standard augmentation to obtain bone
healing, this control may be variable due to the patient and
the surgical variability. Besides, no reference studies are avail-
able about the eﬀectiveness of ICA to support bone healing in
nonunions. Recent data can only be obtained from its use as
controls in other studies [8, 26], but the variability in
the obtention of ICA and the subsequent complications
[7, 27, 28] foster the proposal of alternatives. We used this
information to quantitatively estimate the expected healing
rates with ICA, although it may vary depending on the type
and location of the nonunion.
The use of cultured hBM-MSCs associated with biomate-
rials to heal long bone nonunions has long been reported. In
2007, Bajada et al. [29] healed a resistant tibial nonunion with
5× 106 BM-MSCs combined with calcium sulphate (CaSO4)
in pellet form. Giannotti et al. [30] treated 8 upper limb non-
unions with expanded MSCs and autologous plasma gel with
CaCl2. Ismail et al. [31] ran a clinical trial on 10 patients with
atrophic nonunions randomizing 5 patients to 15 million
autologous BM-MSCs, hydroxyapatite granules, and internal
ﬁxation, with 5 controls with ICA. Larger defects were also
treated by these techniques. Marcacci et al. [32] reported 4
patients with diaphyseal bone defects treated with 20× 106
expanded BM-MSCs combined with cylinders of 100%
porous hydroxyapatite, with bone healing. Dilogo et al. [33]
reported a case of segmental tibial defect treated with
50× 106 BM-MSCs, hydroxyapatite (HA) granules, and bone
morphogenic protein 2 (BMP-2). Therefore, proofs of con-
cept are published and feasibility is conﬁrmed by numerous
authors, although the consensus is that controlled random-
ized clinical trials will have to clarify deﬁnitively the eﬀective-
ness and the cost/beneﬁt superiority of the tissue engineering
approach compared to other methods of bone reconstruction
[29–33].
The dose of expanded cells in previously published stud-
ies is highly variable, partly dependent on the available tech-
nology. In a previous project (FP7-REBORNE), the current
IMP was developed and approved for clinical trials (EudraCT
2011-005441-13 and EudraCT 2012-002010-39), and the
attained dose covered the requisites of the current trial, that
is 200 million cells, expanded from 25–35mL of bone mar-
row. Currently, the optimum dose to heal nonunions in long
bones is unknown. Maximizing the dose to be implanted has
been the most frequent strategy in many ongoing declared
trials. Our high dose (200 million cells) and even the low dose
(100 million cells) compare favourably with previously pub-
lished bone marrow-derived cell products checked for eﬃ-
cacy (15 million cells used by Ismail et al. [31], 20 million
cells by Labibzadeh et al. [34]).
Diﬃculties are encountered to deﬁne the sample size, the
randomization procedure, and the study design due to the
scarcity of comparable studies. A multicentric, randomized
Table 3: ORTHOUNION arms of treatment description.
Study arm Treatment Dosage Administration
G1: ICA (active comparator arm) Iliac crest autograft 10 cc
Local administration under
surgical procedure of
nonunions
G2A: high dose of BM-MSC+B
(experimental arm) Expanded bone marrow
mesenchymal stem cells, plus
biomaterial (MBCP+)
200× 106 cells in 10 cc of biomaterial
G2B: low dose of BM-MSC+B
(experimental arm) 100× 10
6 cells in 10 cc of biomaterial
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study was planned to ascertain that, having standardized the
ATMP in four countries (France, Germany, Italy, and
Spain), patients could receive analogous treatment from
diﬀerent GMP facilities in diﬀerent hospitals. First, this
requires agreement of the national regulators, and a volun-
tary harmonization procedure (VHP) was launched within
the European Union [35]. Second, stratiﬁcation by produc-
tion centre has been planned for the randomization proce-
dure, and this will enable to similarly assess cell production
in all centres.
The sample size calculations have been based on success
rates with ICA as the control on bone healing multicentric
trials [8]. Scarcity of references (both for controls and tech-
nology under evaluation) is observed in the literature. Of
note, no direct head-to-head comparison in a well-designed
randomized clinical trial has been previously conducted with
ICA andMSCs. In this scenario with uncertainties in the ﬁnal
success rates and in the ﬁnal delta of superiority, it is also
noted that very small rate changes in those assumptions
may have an impact in the actual statistical power. However,
clinical relevance of the potential superiority of the technique
would not be clearly deﬁned unless the success rate is clearly
higher. Furthermore, other reasons for failure besides the
augmentation with the ATMP need to be excluded by the
clinical trial committee. Foreseen reasons of failure unrelated
to the ATMP include unstable ﬁxation or other mechanical
issues, inappropriate placement of the biomaterial with cells
or the bone autograft (on-lay apposition instead of the rec-
ommended in-lay application), or intraoperative complica-
tions (intraoperative fractures or other distortion). Those
cases will not be evaluated by PP although ITT analysis will
be performed. Justiﬁcation of the noninferiority of the lower
versus the higher dose of hBM-MSCs is also a potential lim-
itation of the study. A pragmatic approach was agreed in a
noninferiority margin of 10% consolidation rate based on
the diﬀerences between ICA controls and technologies
designed to enhance bone healing in retrospective [26] and
prospective [8] studies. This diﬀerence of 10% could be con-
sidered clinically irrelevant.
Unfortunately, many published studies and clinical trials
on regenerative strategies to promote bone healing fail to
include suﬃcient detail on the treated injuries and on the
implanted cell product. This precludes interpretation of
the outcomes and comparison among studies. Besides, vari-
ability may not permit other investigators to replicate the
study conditions and results. To drive conclusions about
the outcomes of a regenerative technology is then a chal-
lenge, given the complexity of biological therapies and the
wide heterogeneity of conditions where bone regeneration
is required.
This phase III clinical trial intended to clarify the role of
bone regenerative therapies based on autologous cell expan-
sion for nonunion of long bones; therefore, it stands as a
standard for any GMP approach in this ﬁeld. The interest
of this study is driven by the treated condition, where the
intrinsic potential of the fracture to heal seems surpassed;
the cell product, with strong preclinical quality assessment
and with strict release criteria to ensure reproducibility;
and the study design, where an ambitious randomized
comparison is intended to clarify the eﬃcacy of cell therapy
versus iliac crest autograft and the eﬃcacy of a higher dose
of 200× 106 expanded BM-MSCs to heal nonunions versus
the lower dose of 100× 106 cells that may represent less cum-
bersome preparation of a more sustainable cell production.
The results will possibly lead to a better understanding of
the clinical application of stem cell technology.
5. Trial Status
The ORTHOUNION EU-H2020 project started on 1 January
2017. This trial received the EudraCT number 2015-000431-
32, and the clinical protocol and IMP dossier (PEI 12-061)
have been submitted for regulatory evaluation through
VHP (9 January 2017) and authorized (19 April 2017) for
France and Spain with a procedure number VHP1031-
VHP2017004. The national phase at AEMPS (Spain) and
ANSM (France) also completed the approval. Furthermore,
the ethical committees of Hospital Universitario Puerta de
Hierro Majadahonda of Madrid, Spain, and the Comité de
Protections des Personnes Est IV of Strasbourg, France, also
granted the authorization of the current clinical protocol.
Germany and Italy are conducting a national phase evalua-
tion with ongoing status.
Ethical Approval
The protocol has been submitted for approval of the regula-
tory authorities of the participant countries and ethics com-
mittees in France, Germany, Italy, and Spain. The study
protocol has been prepared in compliance with the Good
Clinical Practice and the Declaration of Helsinki, following
the International Conference Harmonization Guidelines.
The study is now being launched in Spain and France, where
all the required approvals have been obtained. The trial will
begin in Germany and Italy only when all the required
approvals have been obtained. The performance of the trial
under double-blind conditions was discussed. Patients would
be unnecessarily exposed to a second invasive procedure
(sham bone marrow extraction or sham iliac crest autograft
obtention) that could increase the pain and the risk of com-
plications, such as infections, and this was ethically consid-
ered unfeasible. The safety aspects of the trial will be
supervised by an independent data safety monitoring board
(DSMB). This board will have 3 members including at least
one expert in clinical trial methodology and statistics and
one orthopaedic surgeon independent from the study. The
DSMB will be established before the start of the trial and will
follow the procedures of a deﬁned DSMB charter for the
ORTHOUNION trial. The DSMB will provide annual but
also urgent reports, including the possibility to advise the
study termination.
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